Hypertension Diagnosis and Management

Essential Initial Workup

• The European Society of Cardiology recommends confirming the diagnosis with out-of-office measurements using ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) when screening office BP is 120-159/70-99 mmHg 1
• The European Society of Cardiology suggests confirming the diagnosis within 1 month using home or ambulatory measurements for office BP ≥160/100 mmHg 1
• The European Society of Cardiology advises immediately excluding hypertensive emergency before proceeding with routine workup when BP ≥180/110 mmHg 1
• The American Heart Association recommends serum electrolytes, including sodium and potassium, as part of the initial workup 2, 3
• The American Heart Association suggests assessing renal function through serum creatinine and estimated glomerular filtration rate (eGFR) 2, 3, 1
• The American Heart Association recommends metabolic assessment, including fasting glucose and lipid profile, as part of the initial workup 2, 3
• The American Heart Association advises urinalysis, including dipstick urine test, as part of the initial workup 2, 3
• The American Heart Association suggests assessing urine albumin-to-creatinine ratio (UACR) to detect early kidney damage 4, 1
• The American Heart Association recommends 12-lead ECG in all patients to detect atrial fibrillation, left ventricular hypertrophy, and ischemic heart disease 4, 2, 1
• The American Heart Association advises documenting body mass index (BMI) and waist circumference, with targets of <94 cm in men and <80 cm in women 3, 1
• The American Heart Association suggests looking for signs suggesting secondary hypertension, including enlarged thyroid, abdominal bruits, delayed femoral pulses, and cushingoid features 3
• The American Heart Association recommends assessing heart rate, as >80 beats/min increases cardiovascular risk 4, 2

Cardiovascular Risk Stratification

• The American Heart Association states that more than 50% of hypertensive patients have additional cardiovascular risk factors that proportionally increase their risk of coronary, cerebrovascular, and renal disease 4, 2
• The American Heart Association recommends identifying high-risk features requiring immediate treatment, including established cardiovascular disease, stroke, diabetes, chronic kidney disease (eGFR <60 mL/min/1.73m²), or familial hypercholesterolemia 4, 1
• The American Heart Association suggests identifying age >65 years, male sex, and family history of premature CVD as high-risk features 4, 2
• The American Heart Association recommends assessing elevated LDL-cholesterol/triglycerides, overweight-obesity, hyperuricemia, and metabolic syndrome as high-risk features 4, 2
• The European Society of Cardiology advises using SCORE2 for ages 40-69 years or SCORE2-OP for ages ≥70 years to assess 10-year CVD risk 1
• The European Society of Cardiology recommends considering patients with SCORE2 or SCORE2-OP ≥10% as being at increased risk and warranting more aggressive management 1

Additional Testing When Indicated

Hypertension-Mediated Organ Damage (HMOD) Assessment

• The American Heart Association states that detection of HMOD is crucial for patients with low-to-moderate overall risk, as it reclassifies them to higher risk and guides treatment intensity 4, 5

Cardiac Evaluation

• The American Heart Association recommends echocardiography when ECG shows abnormalities or patient has signs/symptoms of cardiac disease to assess left ventricular hypertrophy, systolic/diastolic dysfunction, and atrial dilation 4, 1, 5

Vascular Assessment

• The American Heart Association suggests carotid ultrasound to detect atherosclerotic plaques and stenosis when clinically indicated 4, 2
• The American Heart Association recommends assessing ankle-brachial index (ABI) for peripheral artery disease in patients with suspected lower extremity disease 4, 2

Renal Imaging

• The American Heart Association advises renal ultrasound or renal artery Duplex when secondary hypertension is suspected to evaluate for renal parenchymal disease, renal artery stenosis, or adrenal lesions 4, 2

Ophthalmologic Examination

• The American Heart Association recommends fundoscopy in patients with BP >180/110 mmHg to detect retinal hemorrhages, papilledema, or signs of malignant hypertension 4, 1
• The European Society of Cardiology suggests performing fundoscopy in hypertensive patients with diabetes 1

Neurological Assessment

• The American Heart Association advises brain CT/MRI when neurologic symptoms are present to detect ischemic or hemorrhagic brain injury, white matter lesions, or cognitive decline 4, 2

Secondary Hypertension Screening

• The American Heart Association states that screening for secondary causes is necessary when clinical features suggest underlying disease, as 20-40% of malignant hypertension cases have identifiable secondary causes 4

Specific Tests for Secondary Causes

• The American Heart Association recommends assessing aldosterone-renin ratio for primary aldosteronism 4, 2
• The American Heart Association suggests assessing plasma free metanephrines for pheochromocytoma 4, 2
• The American Heart Association advises assessing late-night salivary cortisol or 24-hour urinary free cortisol for Cushing syndrome 4, 2
• The American Heart Association recommends assessing renal artery imaging (CT/MR angiography or Duplex ultrasound) for renal artery stenosis 4, 2

Additional Laboratory Tests

• The American Heart Association suggests assessing serum uric acid levels, as elevated levels are found in 25% of hypertensive patients; treatment is recommended if >6 mg/dL with gout symptoms 4, 2, 5
• The American Heart Association recommends assessing liver function tests 4, 2
• The European Society of Cardiology advises repeating creatinine, eGFR, and UACR at least annually if moderate-to-severe CKD is diagnosed 1

Standardized Initial Work‑up and Risk Assessment for Newly Diagnosed Hypertension

Confirmation of Sustained Hypertension

• Out‑of‑office blood pressure monitoring is required to confirm hypertension when office readings are 120‑159 mmHg systolic or 70‑99 mmHg diastolic. The European Society of Cardiology (ESC) recommends ambulatory or home BP measurement before any further evaluation. 6
• If office BP is ≥160/100 mmHg, confirmation with home or ambulatory monitoring should be obtained within one month. ESC guidance emphasizes timely verification to avoid misclassification. 6
• For office BP ≥180/110 mmHg, an urgent assessment for hypertensive emergency must be performed before routine work‑up. ESC advises immediate exclusion of end‑organ damage. 6

Mandatory Baseline Laboratory and ECG Evaluation

• Serum electrolytes (sodium, potassium) should be measured in every newly diagnosed hypertensive patient. ACC guideline lists this as a core metabolic test. 7
• Serum creatinine with estimated glomerular filtration rate (eGFR) is required to assess renal function. ACC recommends this for baseline kidney evaluation. 7
• Fasting blood glucose should be obtained to screen for diabetes mellitus. ACC includes glucose testing in the initial panel. 7
• A complete lipid profile (total cholesterol, LDL‑C, HDL‑C, triglycerides) is essential for cardiovascular risk stratification. ACC specifies lipid assessment as a standard test. 7
• Urinalysis (dipstick) and urine albumin‑to‑creatinine ratio (UACR) are required to detect proteinuria or early kidney damage. ACC recommends both dipstick and quantitative albumin assessment. 7
• Complete blood count (CBC) should be performed to identify anemia or other hematologic abnormalities. ACC includes CBC in the basic work‑up. 7
• Thyroid‑stimulating hormone (TSH) measurement is advised to uncover thyroid disorders that may influence blood pressure. ACC lists TSH as an essential screen. 7
• A 12‑lead electrocardiogram is mandatory to identify left ventricular hypertrophy, atrial fibrillation, or ischemic changes. Both ACC and ESC consider ECG a required baseline test. [7][6]

Focused Clinical History

• Medication review must include current antihypertensives, adherence, and agents that raise BP (NSAIDs, systemic steroids, sympathomimetics, cocaine, amphetamines). ESC emphasizes this review to detect reversible contributors. [8][7]
• Inquiry about symptoms suggestive of secondary hypertension (e.g., muscle cramps/weakness indicating hypokalemia, palpitations/heat intolerance for hyperthyroidism, weight loss, polyuria, easy bruising for Cushing’s syndrome). ACC highlights these red‑flag symptoms. 7
• Family history of premature cardiovascular disease (men < 55 y, women < 65 y), hypertension, or kidney disease should be documented. ESC recommends this for risk estimation. [8][7]
• Standard cardiovascular risk factors—smoking, diabetes, dyslipidemia, obesity—must be recorded. ESC includes these in the risk assessment. [8][7]

Targeted Physical Examination

• Measure blood pressure in both arms; a inter‑arm difference >10 mmHg suggests vascular disease. ESC advises this as a screening maneuver. 8
• Perform orthostatic BP measurements at 1 min and 3 min after standing; a drop ≥20 mmHg systolic or ≥10 mmHg diastolic is abnormal. ESC defines these thresholds for orthostatic hypotension. 8
• Resting heart rate >80 bpm independently predicts cardiovascular events and should be noted. ESC cites elevated HR as a prognostic marker. 8
• Fundoscopic examination is indicated when BP exceeds 180/110 mmHg to detect retinal hemorrhages or papilledema. ESC recommends fundoscopy in severe hypertension. 6

Cardiovascular Risk Stratification

• Age ≥55 y in men and ≥65 y in women, male sex, dyslipidemia (total cholesterol > 190 mg/dL, LDL‑C > 115 mg/dL, HDL‑C < 40 mg/dL in men or < 46 mg/dL in women, triglycerides > 150 mg/dL), obesity (BMI ≥ 30 kg/m² or waist ≥ 102 cm men / ≥ 88 cm women), and family history of premature CVD are documented risk enhancers. ESC lists these variables for SCORE2 calculation. 8

Screening for Secondary Hypertension (Targeted Indications)

• Hypokalemia (spontaneous or diuretic‑induced) warrants evaluation for primary aldosteronism. ACC recommends measuring the aldosterone‑renin ratio in this context. 7
• Presence of an abdominal bruit should trigger imaging for renovascular disease. ACC cites bruit as a key clinical clue. 7
• Symptoms suggestive of pheochromocytoma (episodic headache, palpitations, sweating) require biochemical screening. ACC advises plasma free metanephrines. 7

Specific Diagnostic Tests for Secondary Causes

Common Pitfalls to Avoid

• Do not skip out‑of‑office BP confirmation; white‑coat hypertension occurs in 15‑30 % of patients. ESC stresses the prevalence and need for verification. 6
• Do not omit orthostatic BP measurement in elderly, diabetic, or poly‑medicated patients; orthostatic hypotension predicts poorer outcomes. ESC highlights its prognostic value. 8
• Do not perform routine secondary‑hypertension screening in all patients; reserve extensive work‑up for the specific clinical scenarios listed above. ACC advises a targeted approach.

All facts are derived from the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) guidelines, with citation identifiers as indicated.